PTC Therapeutics, Inc. Stock News

PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

California-based Palo Alto Investors increased its stake in PTCT by 456,144 shares in the third quarter, adding approximately $33.1 million in value. The change represents approximately 4.4% of reportable assets under management.

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

PTC's strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its bet.

WARREN, N.J., Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees.

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D.

Emma Reeve recently exercised some PTC Therapeutics stock options and sold the shares immediately. Reeve is an independent board director at PTC Therapeutics.

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE: IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on F...